Lyra Therapeutics (LYRA) Projected to Post Earnings on Thursday

Lyra Therapeutics (NASDAQ:LYRA) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $0.44 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

Lyra Therapeutics Price Performance

Shares of NASDAQ LYRA opened at $1.26 on Thursday. The company has a 50 day simple moving average of $2.09 and a 200-day simple moving average of $4.40. The company has a market capitalization of $2.23 million and a P/E ratio of -0.05. Lyra Therapeutics has a 1 year low of $0.91 and a 1 year high of $37.50.

Hedge Funds Weigh In On Lyra Therapeutics

Several large investors have recently made changes to their positions in the stock. DRW Securities LLC purchased a new position in shares of Lyra Therapeutics during the 4th quarter worth approximately $52,000. Citadel Advisors LLC purchased a new stake in Lyra Therapeutics in the third quarter valued at approximately $128,000. Finally, Bank of America Corp DE lifted its stake in Lyra Therapeutics by 33.7% during the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after purchasing an additional 7,190 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lyra Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lyra Therapeutics presently has an average rating of “Reduce” and a consensus price target of $100.00.

Lyra Therapeutics Company Profile

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).